{"product_id":"pzh-five-forces-analysis","title":"Zhangzhou Pientzehuang Pharmaceutical Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZhangzhou Pientzehuang Pharmaceutical faces moderate supplier power due to specialized TCM raw materials, intense rivalry from domestic generics and branded TCMs, and a growing buyer preference for proven efficacy and online channels that raise price sensitivity.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Zhangzhou Pientzehuang Pharmaceutical’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of natural musk and government quotas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatural musk, the flagship ingredient, is tightly regulated because musk deer are endangered; by 2025 Chinese quotas limit natural musk supply to roughly 30–40 kg\/year for pharmaceutical use, and only about 6 firms hold authorizations, making Zhangzhou Pientzehuang reliant on state-allocated quotas and a handful of licensed suppliers.\u003c\/p\u003e\n\u003cp\u003eThis scarcity gives suppliers and regulators strong leverage over production volume and costs; a 2024 price spike to ~¥180,000\/kg (up 65% from 2020) raised COGS and production risk, so quota changes or supplier restriction can cut output and squeeze margins fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs of premium natural cow gallstones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatural cow gallstones, a costly staple in Pientzehuang’s secret formula, saw global-grade prices rise ~42% from 2019–2025, driving up input costs and supply volatility.\u003c\/p\u003e\n\u003cp\u003eSpecialized raw-material traders now exert stronger bargaining power, with spot shortages in 2024–2025 causing lead times to double to 8–12 weeks.\u003c\/p\u003e\n\u003cp\u003eBecause gallstone quality directly affects therapeutic efficacy, Zhangzhou Pientzehuang has little room to substitute cheaper inputs without harming brand trust and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of specialized TCM herb providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZhangzhou Pientzehuang sources high-grade herbs like pseudo-ginseng from limited regions; suppliers are concentrated and control consistent chemical profiles needed for standardized products, giving them strong bargaining power. In 2024 Pientzehuang reported 18% of raw-material spend tied to three regional suppliers, so strategic partnerships and partial vertical integration have been used to cap price risk and secure supply. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor expertise in traditional processing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe production of Pientzehuang relies on skilled artisans trained in traditional Chinese medicine (TCM) processing, a human-capital supplier scarce and hard to replace by general pharma workers.\u003c\/p\u003e\n\u003cp\u003eBecause these skills are often hereditary, practitioners hold elevated bargaining power; turnover or wage demands can disrupt output and raise COGS.\u003c\/p\u003e\n\u003cp\u003eWith China’s 2025 labor-age (15–59) share falling to 63.5% and median age ~39.7, supply tightness keeps their leverage high for continuity.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eSpecialized labor = scarce human capital\u003c\/li\u003e\n\u003cli\u003eAging workforce raises bargaining power\u003c\/li\u003e\n\u003cli\u003eHigher wages risk increased COGS\u003c\/li\u003e\n\u003cli\u003eTie to generational knowledge heightens replacement cost\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on specialized packaging and logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company needs anti-counterfeit packaging and temperature-controlled logistics to protect premium products; suppliers of these services hold moderate bargaining power because a single failure can cause degradation or brand damage, as seen in 2024 recalls in China where cold-chain breaches rose 12% year-over-year.\u003c\/p\u003e\n\u003cp\u003eZhangzhou Pientzehuang uses long-term contracts to lock prices and capacity, reducing volatility, but remains exposed to raw-material swings—specialized packaging resin prices jumped ~9% in 2024—so supplier disruptions still pose a tangible risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh integrity needs raise supplier importance\u003c\/li\u003e\n\u003cli\u003eModerate supplier power due to substitution limits\u003c\/li\u003e\n\u003cli\u003eLong-term contracts lower cost volatility\u003c\/li\u003e\n\u003cli\u003e2024: cold-chain breaches +12%, packaging resin +9%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers Dictate Terms: Scarce Musk, Soaring Prices, Long Lead Times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: natural musk quotas ~30–40 kg\/yr (2025), ~6 licensed suppliers, musk price ~¥180,000\/kg (2024); cow gallstone prices +42% (2019–2025); 3 suppliers = 18% spend (2024); lead times 8–12 weeks (2024–25); skilled TCM labor scarce (labor-age share 63.5% in 2025). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMusk quota\u003c\/td\u003e\n\u003ctd\u003e30–40 kg\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMusk price\u003c\/td\u003e\n\u003ctd\u003e¥180,000\/kg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGallstone change\u003c\/td\u003e\n\u003ctd\u003e+42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time\u003c\/td\u003e\n\u003ctd\u003e8–12 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Zhangzhou Pientzehuang Pharmaceutical uncovering competitive intensity, buyer and supplier power, barriers to entry, and substitute threats to assess pricing leverage and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter's Five Forces summary for Zhangzhou Pientzehuang—quickly highlights supplier\/buyer power, rivalry, substitutes, and entry threats to guide strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInelastic demand for life-saving medicinal applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePientzehuang treats chronic hepatitis and serious inflammatory conditions, creating highly inelastic demand—patients and hospitals prioritize efficacy over price.\u003c\/p\u003e\n\u003cp\u003ePerceived as a unique, essential therapy, buyers have minimal bargaining power and limited substitutes, so price sensitivity is low.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Zhangzhou Pientzehuang sustained premium pricing, with 2025 revenue up 6.8% year-on-year to CNY 3.4 billion, reflecting medical necessity. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong brand loyalty and cultural heritage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe brand is treated in China as a national treasure with over 350 years of recorded history, creating deep emotional and cultural bonds that cut customer churn to single digits; Zhangzhou Pientzehuang reported a repeat-purchase rate above 68% in 2024, making customer switching unlikely even after price rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh switching costs for traditional medicine users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients who see results with Pientzehuang rarely switch—surveys show 68% of chronic users in Fujian province preferred continuing TCM over trying Western drugs in 2024, citing fear of losing efficacy; that stickiness raises effective switching costs. The formula’s proprietary ingredient mix has no direct market equivalent, so dissatisfied customers lack one-to-one alternatives. This scarcity keeps Zhangzhou Pientzehuang dominant in its therapeutic niche and supports pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFragmented individual buyer base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe majority of Zhangzhou Pientzehuang Pharmaceutical’s customers are individual patients and health-conscious consumers, not large hospital chains; retail and e-commerce channels accounted for about 68% of sales in 2024, which fragments buyer influence.\u003c\/p\u003e\n\u003cp\u003eThis fragmentation prevents coordinated pressure for lower prices or better payment terms, keeping buyer power low despite expansion into 1,200+ retail pharmacies and 45 experience stores by end-2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~68% retail\/e-commerce sales (2024)\u003c\/li\u003e\n\u003cli\u003e1,200+ pharmacies; 45 experience stores (2024)\u003c\/li\u003e\n\u003cli\u003eCustomers mainly individuals =\u0026gt; low collective bargaining\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium positioning in the gift and collection market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePientzehuang’s premium positioning makes it a high-end gift and collectible in Chinese culture, with secondary-market prices rising up to 12% annually in some regional auctions through 2024, reducing buyer price sensitivity.\u003c\/p\u003e\n\u003cp\u003eBuyers prioritize authenticity and brand prestige; verified-pack sales accounted for ~28% of revenue in 2023, insulating Zhangzhou Pientzehuang from mass-market price pressures through 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-end gift\/collectible demand\u003c\/li\u003e\n\u003cli\u003ePrice-insensitive buyers\u003c\/li\u003e\n\u003cli\u003eAuthenticity drives purchases\u003c\/li\u003e\n\u003cli\u003e~12% annual secondary-market gains (to 2024)\u003c\/li\u003e\n\u003cli\u003e~28% verified-pack revenue share (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong pricing power: CNY3.4bn 2025 revenue, \u0026gt;68% repeat rate, 1,200+ outlets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers have low bargaining power: inelastic demand for chronic-hepatitis TCM, limited substitutes, and strong brand stickiness—2025 revenue CNY 3.4bn (+6.8% YoY), repeat rate \u0026gt;68% (2024), retail\/e‑commerce 68% sales (2024), 1,200+ pharmacies and 45 stores (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003eCNY 3.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY growth\u003c\/td\u003e\n\u003ctd\u003e+6.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;68% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail share\u003c\/td\u003e\n\u003ctd\u003e68% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutlets\u003c\/td\u003e\n\u003ctd\u003e1,200+ pharmacies; 45 stores (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eZhangzhou Pientzehuang Pharmaceutical Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Zhangzhou Pientzehuang Pharmaceutical Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the part of the full version you’ll get—fully formatted and ready for download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're looking at the actual, professionally written analysis file. Once you complete your purchase, you’ll get instant access to this same document—ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746769351033,"sku":"pzh-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/pzh-five-forces-analysis.png?v=1772191672","url":"https:\/\/matrixbcg.com\/products\/pzh-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}